EUVIMEDEUVIMED entdecken
Crossref

Leucine-Rich Alpha-2 Glycoprotein Is a Reliable Serum Biomarker for Evaluating Clinical and Endoscopic Disease Activity in Inflammatory Bowel Disease

Takahiro Shimoyama, Takayuki Yamamoto iD, Shigeyuki Yoshiyama, Ryutaro Nishikawa, Satoru Umegae

Inflammatory Bowel Diseases · 2023

DOI: 10.1093/ibd/izac230 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, 2023. Verfasst von Takahiro Shimoyama und 4 weiteren Autor:innen. Beteiligte Einrichtung: Inflammatory Bowel Disease Center, Yokkaichi Hazu Medical Center, Yokkaichi, Mie, Japan. Hauptthemen laut MEDLINE: Inflammatory Bowel Diseases, Colitis, Ulcerative, Crohn Disease. Die Arbeit wurde bisher 53-mal zitiert (Crossref) und nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Leucine-rich alpha-2 glycoprotein (LRG) is a novel serum biomarker for inflammation in inflammatory bowel disease (IBD). This prospective study aimed to compare the value of LRG with C-reactive protein (CRP) and fecal calprotectin for evaluating clinical and endoscopic disease activity in patients with IBD.

Methods

At entry, clinical and endoscopic disease activity was assessed in 267 patients with IBD (ulcerative colitis [UC] 203; Crohn’s disease [CD] 64), and the levels of LRG, CRP and fecal calprotectin were measured. The accuracy of the biomarkers for the detection of clinical and endoscopic disease activity was determined by the area under the receiver operating characteristic curve.

Results

Leucine-rich alpha-2 glycoprotein showed a significant relationship with the clinical and endoscopic severity in both UC and CD (both diseases, P < .0001). In the clinical assessment of UC, the accuracy of LRG was significantly higher than that of CRP (0.73 vs 0.63; P < .001). In the endoscopic assessment of UC, the accuracy of LRG was significantly higher than that of CRP (P = .01), but it was significantly lower than that of fecal calprotectin (P = .009; LRG, 0.80; CRP, 0.72; fecal calprotectin, 0.91). In the clinical and endoscopic assessment of CD, the accuracy was not significantly different between the biomarkers (clinical activity: LRG, 0.71; CRP, 0.64; fecal calprotectin, 0.66; in endoscopic activity: LRG, 0.79; CRP, 0.78; fecal calprotectin, 0.81).

Conclusions

Leucine-rich alpha-2 glycoprotein is a reliable serum biomarker for the assessment of clinical and endoscopic disease activity in patients with IBD. It can be an alternative to CRP for the assessment of UC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Inflammatory Bowel DiseasesColitis, UlcerativeCrohn DiseaseHumansLeucineProspective StudiesBiomarkersC-Reactive ProteinFecesLeukocyte L1 Antigen ComplexGlycoproteinsSeverity of Illness Index

Stichwörter der Autor:innen

C-reactive proteinCrohn’s diseasefecal calprotectinleucine-rich alpha-2 glycoproteinulcerative colitis

Substanzen

LeucineBiomarkersC-Reactive ProteinLeukocyte L1 Antigen ComplexGlycoproteins

Autor:innen und Institutionen

  • Inflammatory Bowel Disease Center, Yokkaichi Hazu Medical Center, Yokkaichi, Mie, Japan.

ORCID-Profile: Takayuki Yamamoto

Zitieren

APA

Shimoyama, T., Yamamoto, T., Yoshiyama, S., Nishikawa, R., & Umegae, S. (2023). Leucine-Rich Alpha-2 Glycoprotein Is a Reliable Serum Biomarker for Evaluating Clinical and Endoscopic Disease Activity in Inflammatory Bowel Disease. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izac230

Vancouver

Shimoyama T, Yamamoto T, Yoshiyama S, Nishikawa R, Umegae S. Leucine-Rich Alpha-2 Glycoprotein Is a Reliable Serum Biomarker for Evaluating Clinical and Endoscopic Disease Activity in Inflammatory Bowel Disease. Inflammatory Bowel Diseases. 2023. doi:10.1093/ibd/izac230

BibTeX
@article{Shimoyama2023,
  author = {Shimoyama, Takahiro and Yamamoto, Takayuki and Yoshiyama, Shigeyuki and Nishikawa, Ryutaro and Umegae, Satoru},
  title = {Leucine-Rich Alpha-2 Glycoprotein Is a Reliable Serum Biomarker for Evaluating Clinical and Endoscopic Disease Activity in Inflammatory Bowel Disease},
  journal = {Inflammatory Bowel Diseases},
  year = {2023},
  doi = {10.1093/ibd/izac230}
}
Kostenlos starten →